Cas No.: | 1380227-11-1 |
Chemical Name: | methyl 3-((4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)methyl)benzoate |
SMILES: | C(OC)(=O)C1=CC=CC(CN2C=C(C3C4=C(C=CC=3)C(=O)C=C(N3CCOCC3)N4)N=N2)=C1 |
Formula: | C24H23N5O4 |
M.Wt: | 445.479 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | CL27c is a cell-permeable, inhaled lipophilic ester prodrug of CL27e, which is a potent, selective pan-class I PI3K inhibitor, CL27c is inactive in PI3K enzymatic assay, once inside the cytoplasm, CL27c is metabolized by unspecific esterases into CL27e; readily reduces Akt/PKB phosphorylation in chronic lymphocytic leukemia (CLL) cells stimulated with anti-IgM antibodies, as well as in murine neutrophils and bone marrow-derived macrophages (BMDM) stimulated with C5a; reduces insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action; reduces inflammation and improves lung function in murine models of acute or glucocorticoid-resistant neutrophilic asthma. |